Faricimab-svoa

Covers intravitreal faricimab‑svoa (Vabysmo) for treatment and continuation therapy of neovascular (wet) AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion and related choroidal/retinal neovascular disorders. Coverage is limited to FDA‑approved or compendia‑supported uses (or off‑label uses supported by two peer‑reviewed articles), requires dosing per authoritative sources, and—for nAMD, DME and RVO indications—generally requires prior bevacizumab trial/failure or a documented clinical reason or shortage to avoid bevacizumab; other indications are considered experimental/investigational and benefits are subject to the member’s plan and state (HCSC Ohio) limitations.

"Coverage of any FDA‑approved drug when prescribed for a use recognized as safe and effective for a given indication in one or more standard medical reference compendia adopted by the U."